Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Report Guidance 4 Clinical Trials by Region 5 Clinical Trials and Average Enrollment by Country 6 Top Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Countries Contributing to Clinical Trials in Central and South America 12 Clinical Trials by G7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 13 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 17 Clinical Trials by Phase in E7 Countries 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials 27 Prominent Drugs 29 Clinical Trial Profile Snapshots 30 Appendix 49 Abbreviations 49 Definitions 49 Research Methodology 50 Secondary Research 50 About GlobalData 51 Contact Us 51 Disclaimer 51 Source 52

List of Tables Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region, 2016* 5 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12 Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14 Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 18 Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 List of Figures Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region (%), 2016* 5 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 12 Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 13 Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17 Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 GlobalData Methodology 50

Shire Plc Nuo Therapeutics, Inc. GlaxoSmithKline Plc Zymenex A/S RegenxBio Inc. Novartis AG Marcus Foundation Inc Fate Therapeutics, Inc. Celgene Corporation Aldagen, Inc.